DebRD_ATL said:The gap between trial results and real-world results is consistent and it is not fraud.
Pushing back on DebRD_ATL here. Small molecule does not automatically mean cheap. Price is set by what the market will bear and by patent life, not by cost of goods, and I would not assume the savings reach patients.
One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
VendorMark said:Small molecule does not automatically mean cheap.
Coming at VendorMark’s question from a different direction. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from pam_columbus — and this may be the naive question:
How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?
Reporting back.
Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.